Dr. Paul Harmatz, MD

Payments from drug and device companies

In 2025, 4 companies reported 31 payments worth $37,137 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 3 companies. The companies reported $683,063 in research payments for these studies, mostly to the institutions running them.

• Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
  Eli Lilly and Company · Active, not recruiting · NCT04411654
• A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia
  BioMarin Pharmaceutical Inc.
• Proof of Concept Study of Vosoritide for the Treatment of Growth Deficits in MPS IVA & VI
  BioMarin Pharmaceutical Inc.
• An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
  BioMarin Pharmaceutical Inc.
• TAK-665-4003: an open-label, multicenter, phase 4 study to assess the effects of a prophylactic immune tolerizing regimen in mps ii treatment-nave patients planned to receive elaprase who are at risk of developing per…
  Takeda Pharmaceuticals U.S.A., Inc.
• A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia
  BioMarin Pharmaceutical Inc.
• Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094
  Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT02412787
• An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
  Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT01506141

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Pediatric Gastroenterology clinicians in Oakland

• Sabina A. Ali, MD
• Elizabeth E. Gleghorn, M.D.
• Arathi Lakhole, M.D, M.P.H
• Prita Mohanty, MD
• Edward J. Rich, MD
• Robert J. Rothbaum, M.D.
• Mala Setty, M.D.
• Joanna Yeh, MD